Results 261 to 270 of about 249,886 (308)
Some of the next articles are maybe not open access.
Immunomodulatory effects of targeted radionuclide therapy
2023It is now clear that conventional radiation therapy can reinstate cell death immunogenicity. Recent preclinical data indicate that targeted radionuclide therapy that irradiate tumors at continuous low dose rate also can elicit immunostimulatory effects and represents a promising strategy to circumvent immune checkpoint inhibitor resistance.
Constanzo, J. +5 more
openaire +2 more sources
Immunomodulatory Therapy for Myelodysplastic Syndromes
International Journal of Hematology, 2007Thalidomide and lenalidomide belong to the proprietary group of immunomodulatory drugs (IMiDs) that display broad biologic and pharmacologic properties. Encouraging results of clinical studies that evaluated the efficacy of thalidomide in patients with myelodysplastic syndromes (MDSs) led to the investigation of its structural analogue, lenalidomide ...
Lubomir, Sokol, Alan F, List
openaire +2 more sources
Immunomodulatory, Immunoablative, and Biologic Therapies
2016Immunosuppressive drugs constitute a heterogeneous group of therapeutic compounds, each with a unique mode of action and toxicity profile (Table 41.1). Their main function is to dampen the immune system – notably T and B lymphocytes – functionally and/or numerically, hence their utility in inducing remission and control of specific rheumatic ...
Van Laar, Jacob M., Simms, Robert W.
openaire +2 more sources
Immunomodulatory therapy for sepsis: an update
Expert Review of Anti-infective Therapy, 2011Currently the treatment mainstay of sepsis is early and appropriate antibiotic therapy, accompanied by aggressive fluid administration, the use of vasopressors when needed and the prompt initiation of measures to support each failing organ. Activated protein C and hydrocortisone, when used accordingly can affect mortality.
Christaki, Eirini +5 more
openaire +3 more sources
Immunomodulatory therapy for inflammatory bowel disease
Journal of Gastroenterology, 2004Patients with inflammatory bowel disease (IBD) have intestinal and extraintestinal symptoms that can greatly impair their quality of life. They must rely on multiple medications with aminosalicylates, corticosteroids, and purine analogues to control these symptoms.
Kazuo, Kusugami +5 more
openaire +2 more sources
Immunomodulatory Therapies: Challenges of Individualized Therapy Strategies
2007"Individualized therapy strategies" involve strategies that allow treatment to be guided by patient-specific conditions. For this, robust biomarkers are needed. Examples of biomarker-guided therapies already in use are the treatment of insulin-dependent diabetes (biomarker: blood glucose level) or the treatment of hypertension (biomarker: blood ...
H D, Volk +5 more
openaire +2 more sources
Future directions in immunomodulatory therapy
Medical Oncology, 2009The role of immunomodulatory-based therapy with thalidomide or lenalidomide is clearly established in the management of patients with myeloma in all phases of their disease. Recent preclinical and clinical works have demonstrated that in addition to combination therapy with dexamethasone, there is significant activity when combined with the proteasome ...
openaire +2 more sources
Recent developments in immunomodulatory therapy
Journal of Allergy and Clinical Immunology, 1985The remarkable gains in basic immunologic knowledge have outpaced improvements in available agents or techniques that can be used to clinically modify the immune response. Many biologic and synthetic immunomodifiers, adjuvants, and drugs with both specific and/or nonspecific effects on immunity have been investigated.
openaire +2 more sources
Immunomodulatory Therapies in Neurologic Critical Care
Neurocritical Care, 2009Neurologic disorders with autoimmune dysregulation are commonly encountered in the critical care setting. Frequently encountered diseases include Guillain-Barré syndrome (GBS), myasthenia gravis, multiple sclerosis, acute demyelinating encephalomyelitis, and encephalitides. Immunomodulatory therapies, including high-dose corticosteroids, plasmapheresis,
Logan M, McDaneld +3 more
openaire +2 more sources
Immunomodulatory Therapies for Renal Cell Carcinoma
Protein & Peptide Letters, 2018Renal Cell Carcinoma (RCC) is the most common tumor originating from the kidneys. In comparison to other solid tumors, RCC is poorly sensitive to conventional therapeutic modalities. As such, metastatic RCC (mRCC) continues to be associated with high rates of morbidity and mortality. Targeted agents have shown remarkable progress in RCC management with
Min, Liu +8 more
openaire +2 more sources